These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29396328)

  • 21. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
    Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
    Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
    Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.
    Groheux D; Majdoub M; Sanna A; de Cremoux P; Hindié E; Giacchetti S; Martineau A; de Roquancourt A; Merlet P; Visvikis D; Resche-Rigon M; Hatt M; Espié M
    Radiology; 2015 Nov; 277(2):358-71. PubMed ID: 25915099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unexpected Abnormal Uptake in the Breasts at Dedicated Breast PET: Incidentally Detected Small Cancers or Nonmalignant Features?
    Satoh Y; Motosugi U; Omiya Y; Onishi H
    AJR Am J Roentgenol; 2019 Feb; 212(2):443-449. PubMed ID: 30476450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
    Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
    Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
    Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
    Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
    Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
    Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of MRI and PET/CT after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity.
    Kim T; Kang DK; An YS; Yim H; Jung YS; Kim KS; Kang SY; Kim TH
    Acta Radiol; 2014 May; 55(4):399-408. PubMed ID: 23963151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D; Hatt M; Hindié E; Giacchetti S; de Cremoux P; Lehmann-Che J; Martineau A; Marty M; Cuvier C; Cheze-Le Rest C; de Roquancourt A; Visvikis D; Espié M
    Cancer; 2013 Jun; 119(11):1960-8. PubMed ID: 23504954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.
    Kostakoglu L; Duan F; Idowu MO; Jolles PR; Bear HD; Muzi M; Cormack J; Muzi JP; Pryma DA; Specht JM; Hovanessian-Larsen L; Miliziano J; Mallett S; Shields AF; Mankoff DA;
    J Nucl Med; 2015 Nov; 56(11):1681-9. PubMed ID: 26359256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dedicated breast PET value to evaluate BI-RADS 4 breast lesions.
    Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares A; Ruibal A; Vázquez-Caruncho M
    Eur J Radiol; 2018 Nov; 108():201-207. PubMed ID: 30396656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT.
    Kalinyak JE; Berg WA; Schilling K; Madsen KS; Narayanan D; Tartar M
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):260-75. PubMed ID: 24085500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
    Jung SY; Kim SK; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Park IH; Lee KS; Shin KH; Lee S; Kim SW; Kang HS; Ro J
    Ann Surg Oncol; 2010 Jan; 17(1):247-53. PubMed ID: 19777177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer.
    Pahk K; Rhee S; Cho J; Seo M; Lee S; Park T; Park S; Lee E; Park KH; Kim C; Eo JS; Kim S; Choe JG
    Anticancer Res; 2014 Aug; 34(8):4447-55. PubMed ID: 25075084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
    Bassa P; Kim EE; Inoue T; Wong FC; Korkmaz M; Yang DJ; Wong WH; Hicks KW; Buzdar AU; Podoloff DA
    J Nucl Med; 1996 Jun; 37(6):931-8. PubMed ID: 8683314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.